eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

This study — called VIGILANT — is testing whether starting a biologic drug called depemokimab early improves outcomes for people with COPD (chronic obstructive pulmonary disease) who have a type of airway inflammation driven by immune cells called eosinophils (Type 2 inflammation). Depemokimab targets a protein called IL-5 to reduce these cells. **You may be eligible if...** - You have been diagnosed with moderate to severe COPD for at least 1 year - Your breathing test (spirometry) shows an FEV1/FVC ratio below 0.70 and FEV1 between 30-80% of what is normal for you - You have an elevated eosinophil (a type of immune cell) count in your blood - You have had at least 1 moderate COPD flare-up (exacerbation) in the past 12 months **You may NOT be eligible if...** - You have very severe COPD (FEV1 below 30%) - You do not have the eosinophilic (Type 2) type of COPD - You have not had any recent exacerbations - You have other health conditions that would interfere with the study Talk to your doctor to see if this trial is right for you.